The Indian government unveiled on 27 July detailed guidelines for twin schemes aimed at driving investments in bulk drug production in the country, against a backdrop of rising drug nationalism and a need to reduce raw materials dependency on China post the COVID-19-led disruption.
India’s Bulk Drugs Incentive Scheme Finds Takers In Mankind, Aarti
FDI Potential Of Bulk Drugs Parks Hazy
As India revealed finer details of two schemes to promote bulk drug production, Mankind Pharma and Aarti Drugs spelled out a preference for chemical synthesis products - they are likely to be joined by more companies reluctant to invest in some that are fermentation-based. Whether a “plug and play” format for bulk drug parks will attract foreign investment remains to be seen.
More from Manufacturing
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
J&J followed in the footsteps of Lilly and Merck, which have announced multibillion-dollar investments in US manufacturing since Donald Trump’s inauguration.
• By
A joint venture with AI specialist Hologen will bring in much-needed cash for the ambitious gene therapy firm.